IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients

• Published in: PloS one Vol. 8; no. 8; p. e70731
• Main Authors: Mahendra, Ankit, Peyron, Ivan, Dollinger, Cécile, Gilardin, Laurent, Sharma, Meenu, Wootla, Bharath, Padiolleau-Lefevre, Séverine, Friboulet, Alain, Boquet, Didier, Legendre, Christophe, Kaveri, Srinivas V., Thaunat, Olivier, Lacroix-Desmazes, Sébastien
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 15.08.2013; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Catalytic - blood; Antibodies, Catalytic - metabolism; Autoantibodies - blood; Autoantibodies - immunology; Biology; Care and treatment; Catalysis; Catalytic antibodies; Desensitization; End-stage renal disease; Engineering Sciences; Enzymatic activity; Enzymes; Female; Graft rejection; Graft Rejection - immunology; Health aspects; Hemophilia; Histocompatibility Antigens - immunology; Humans; Hydrolysis; Immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin G - metabolism; Immunoglobulins; Immunoglobulins, Intravenous - administration & dosage; Immunology; Immunosuppression; Immunosuppressive agents; Inflammatory diseases; Intravenous administration; Kidney diseases; Kidney Transplantation; Lymphocytes; Male; Medical prognosis; Medical research; Medicine; Middle Aged; Nephrology; Nephropathy; Other; Patients; Peptides; Prognosis; Reduction; Rejection; Renal failure; Rodents; Transplantation; Transplants & implants; Young Adult; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0070731

Catalytic antibodies are immunoglobulins endowed with enzymatic activity. Catalytic IgG has been reported in several human autoimmune and inflammatory diseases. In particular, low levels of catalytic IgG have been proposed as a prognostic marker for chronic allograft rejection in patients undergoing kidney transplant. Kidney allograft is a treatment of choice for patients with end-stage renal failure. Intravenous immunoglobulins, a therapeutic pool of human IgG, is used in patients with donor-specific antibodies, alone or in conjunction with other immunosuppressive treatments, to desensitize the patients and prevent the development of acute graft rejection. Here, we followed for a period of 24 months the levels of catalytic IgG towards the synthetic peptide Pro-Phe-Arg-methylcoumarinimide in a large cohort of patients undergoing kidney transplantation. Twenty-four percent of the patients received IVIg at the time of transplantation. Our results demonstrate a marked reduction in levels of catalytic antibodies in all patients three months following kidney transplant. The decrease was significantly pronounced in patients receiving adjunct IVIg therapy. The results suggests that prevention of acute graft rejection using intravenous immunoglobulins induces a transient reduction in the levels of catalytic IgG, thus potentially jeopardizing the use of levels of catalytic antibodies as a prognosis marker for chronic allograft nephropathy.